TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02604355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match RO7020322.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match RO7020322.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match RO7020322.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Oral dosing with placebo capsules to match RO7020322.
Study: NCT03756922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector
Study: NCT02604355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020322
Description: Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020322
Description: Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020322
Description: Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020322
Description: Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
Study: NCT03011983

Intervention type: DEVICE
Intervention: MEG
Description: MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.

Intervention type: DEVICE
Intervention: MEG
Description: MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.

Intervention type: DEVICE
Intervention: MRI
Description: MRI is a non-invasive imaging modality that provides measures of brain structure.

Intervention type: DEVICE
Intervention: MRI
Description: MRI is a non-invasive imaging modality that provides measures of brain structure.

Intervention type: BEHAVIORAL
Intervention: Neuropsychology assessment
Description: A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.

Intervention type: BEHAVIORAL
Intervention: Neuropsychology assessment
Description: A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
Study: NCT01259375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
Study: NCT01167556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Motivational Intervention
Description: A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Motivational Intervention
Description: A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
Study: NCT03825068

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP Block
Description: 20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: general anesthetic
Description: patient receive general anaesthetic only
Study: NCT02140983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: 90 days of liraglutide up to 1.8mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication
Study: NCT00235066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI
Description: PCI with Cypher Sirolimus-Eluting Stent
Study: NCT03756922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR potentiator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR potentiator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR potentiator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL176
Description: CFTR potentiator
Study: NCT01355822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PETN
Description: Pentaerythrithyltetranitrate: 80 mg orally twice a day
Study: NCT01968902

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incabotulinumtoxinA
Description: A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
Study: NCT01355822

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: orally, twice daily
Study: NCT03577925

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV genotype test
Description: HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.

Intervention type: DIAGNOSTIC_TEST
Intervention: HPV genotype test
Description: HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
Study: NCT01968902

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection on the day of injection visit
Study: NCT00848978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week aerobic and strength training program
Description: Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
Study: NCT01547247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope
Description: Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion colonoscopy
Description: Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
Study: NCT01381458

Intervention type: DRUG
Intervention: FSC
Description: fluticasone propionate / salmeterol xinofoate combination

Intervention type: DRUG
Intervention: ACs
Description: tiotropium alone, ipratropium alone, or in combination with albuterol
Study: NCT00802438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: up to three monthly doses of 750mg i.v. mepolizumab
Study: NCT02878460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monitoring with ORI + SpO2
Description: If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called.

Intervention type: OTHER
Group type: OTHER
Intervention: monitoring with SpO2
Description: If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called.
Study: NCT02453477

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Description: Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Description: Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Description: Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
Study: NCT01156402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families-Childhood Obesity Prevention and Oral Health
Description: The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families-Childhood Obesity Prevention and Oral Health
Description: The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
Study: NCT04967586

Intervention type: OTHER
Intervention: No intervention, questioner only
Description: questioner only
Study: NCT03298256

Intervention type: RADIATION
Intervention: EOS X-rays
Description: Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
Study: NCT01917357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quinvaxem in Uniject
Study: NCT02001077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain (CBT-P)
Study: NCT01917357

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quinvaxem in single dose vials
Study: NCT03788668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyoid suspension
Description: Hyoid suspension will be done with barbed reposition pharyngoplasty
Study: NCT00902980

Intervention type: OTHER
Intervention: Chart Review
Description: Chart review of patients / graft outcome in renal transplant recipients

Intervention type: OTHER
Intervention: Chart Review
Description: Chart review of patients / graft outcome in renal transplant recipients
Study: NCT02134613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-anti-TNF-alpha Scintigraphy
Description: 99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
Study: NCT01233414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Program
Description: The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
Study: NCT01619462

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar 13 and Synflorix
Description: 260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar 13 and Synflorix
Description: 260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
Study: NCT02906696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03410810

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopmental/Neuropsychological Assessment
Description: Standardized Cognitive and Developmental Tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopmental/Neuropsychological Assessment
Description: Standardized Cognitive and Developmental Tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopmental/Neuropsychological Assessment
Description: Standardized Cognitive and Developmental Tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopmental/Neuropsychological Assessment
Description: Standardized Cognitive and Developmental Tests
Study: NCT00986986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release niacin
Description: Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
Study: NCT02160028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthetics and extended information before dental treatment
Description: The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anesthetics and standard information before dental treatment
Description: The standard information is short and concise, telling in neutral words what to expect.
Study: NCT02736591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone-Releasing Hormone
Description: Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
Study: NCT03233204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT00412594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04272606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Antifibrinolytic Agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual Acuity Exam
Description: Supplemented into standard of care daily neurological exam on day of surgery and day after

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Acuity Exam
Description: Supplemented into standard of care daily neurological exam on day of surgery and day after

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Description: 3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Description: 3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
Study: NCT02795845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum
Description: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule without active ingredient
Study: NCT01813513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration
Study: NCT04012658

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02879799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement Family Integrated Care
Description: Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
Study: NCT02949076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
Study: NCT01813513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: 50 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 mg capsule for oral administration
Study: NCT02817698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
Study: NCT00550862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)